Načítá se...
A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation
BACKGROUND: Currently, there are no effective medications to reverse periodontal disease (PD)-induced bone loss. The objective of this study was to test a new anabolic compound, LLP2A-Ale, or with the combination treatment of mesenchymal stromal cell (MSC), in the treatment of bone loss secondary to...
Uloženo v:
| Vydáno v: | BMC Pharmacol Toxicol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7664094/ https://ncbi.nlm.nih.gov/pubmed/33187558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-020-00454-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|